This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
biotechnology biotechs medical pharmaceuticals
Stock Market News for Jan 7, 2026
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday, led by materials, healthcare and chip stocks.
medical semiconductor
Company News for Jan 7, 2026
by Zacks Equity Research
Companies in The News Are: XOM, AIG, STX, UNH
energy medical
ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?
by Indrajit Bandyopadhyay
ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.
medical medical-devices
Should You Buy ACB Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Aurora Cannabis faces uneven gains from marijuana reclassification as medical cannabis drives growth, while weak consumer sales affect optimism.
marijuana medical pot-stocks
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
by Zacks Equity Research
Envista's global expansion, bolt-on acquisitions, and strong balance sheet support growth, even as currency swings pressure sales.
medical
TEM's Stable Solvency and Financial Strength Are Gaining Attention
by Sridatri Sarkar
Tempus AI posts a strong Q3 2025 balance sheet with $760M cash, no current debt, and positive adjusted EBITDA, boosting flexibility and solvency.
medical
IDEXX Stock Up 64.7% in a Year: What's Driving the Growth?
by Zacks Equity Research
IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.
medical medical-devices
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
by Zacks Equity Research
Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.
medical medical-devices
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
by Sundeep Ganoria
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
biotechs medical